Mutant G-CSF fusion protein, and preparation and use thereof

US8785597B2 · kind B2 · utility

Assignee

• JIANGSU T-MAB BIOPHARMA CO., LTD · CN

Inventors

• Xiaofang Wen · Hangzhou City, CN
• Yiliang Wu · Oakville, CA
• Yefei Wang · Gouli, CN
• Zhiyu Yang · Dublin, US
• Min Fan · Xi'an, CN
• Yujiao Wang · Gouli, CN
• Xiaochun Fang · Gouli, CN
• You Lu · Gouli, CN

Key dates

• Filing date: Jun 30, 2010
• Grant date: Jul 22, 2014
• Expiry date: Jun 30, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.